Targeting ApoD with Antibody-Drug Conjugates: A New Era in Senolysis for Skin Rejuvenation
A study published in the International Journal of Molecular Sciences has revealed a novel senolysis approach that specifically targets senescent cells in aging skin, paving the way for potential clinical applications in treating pathological skin aging and related diseases.
As we age, senescent cells accumulate in our skin, causing age-related changes and a decline in functional efficiency. These cells are characterized by the expression of certain markers, one of which is apolipoprotein D (ApoD), a protein found on senescent dermal fibroblasts.
In this study, researchers have developed a unique approach using a monoclonal antibody against ApoD, combined with a secondary antibody conjugated with the cytotoxic drug pyrrolobenzodiazepine (PBD). The findings reveal that ApoD functions as a surface marker of senescent cells, and the antibody is taken up and internalized only by such cells, leaving young cells unharmed.
The concurrent administration of the antibody with the PBD-conjugated secondary antibody specifically eliminated senescent cells, reducing their number in the dermis of aging mice and significantly improving the senescent skin phenotype.
This innovative antibody–drug conjugate treatment provides a proof-of-principle evaluation for a novel approach to specifically eliminate senescent cells using marker proteins. The potential clinical applications of this approach could revolutionize the treatment of pathological skin aging and related diseases by effectively removing senescent cells.
Join Skin Ageing & Challenges on November 7-8, 2024 at Corinthia Palace Malta! The conference will cover all recent advances in skin rejuvenation and senolysis, shedding light on recently developed strategies and innovations.
Did you like the news ? Please share it with your circle.